Makary’s priorities: Faster reviews, domestic manufacturing, and AI
Regulatory NewsJoanne S. Eglovitch
Artificial intelligence/machine learning (AI/ML)Audit/inspectionBiologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)Clinical TrialsCoronavirus/COVID-19ManufacturingPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)